| Literature DB >> 35696391 |
Amy L Shafrir1,2, Allison F Vitonis2,3, Britani Wallace2,3, Amy D DiVasta1,2, Jenny Sadler Gallagher1,2, Naoko Sasamoto2,3, Marc R Laufer2,3,4, Kathryn L Terry2,3,5, Stacey A Missmer1,2,5,6.
Abstract
Endometriosis affects reproductive-aged females and varies considerably in terms of symptom presentation, morphologic features, and treatment response. Most studies investigating symptom recurrence after an endometriosis-related surgery have been conducted among adults. The Endometriosis pain QUality aftEr Surgical Treatment (EndoQUEST) Study was established to assess characteristics and biomarkers that are associated with pain remediation and improved quality of life after an endometriosis-related surgery among adolescents and young adults. This paper describes the EndoQUEST methodology, summarizes baseline descriptive factors, and compares characteristics by participant retention status. We enrolled 100 surgically-confirmed endometriosis participants aged 12-23 years who provided questionnaire data on reproductive and behavioral factors, pain characteristics and quality of life at three time points; before surgery, 6 weeks to 26 weeks after surgery, and 1 year after surgery. Among these 100 participants, 88 provided blood and/or saliva at all three time points, while 12 provided blood and/or saliva samples only before surgery and 6 to 26 weeks after surgery. There was little evidence of lost to follow-up at 1 year after surgery due to pain symptoms, as pain and quality of life characteristics were similar between participants who completed the questionnaire 1 year after surgery and those who did not. Analyses utilizing these longitudinal data will advance personalized treatment decision making for adolescents and young adults with endometriosis.Entities:
Mesh:
Year: 2022 PMID: 35696391 PMCID: PMC9191708 DOI: 10.1371/journal.pone.0269858
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.752
Fig 1Schematic of the EndoQUEST questionnaire and biospecimen collection.
Fig 2Inclusion (black boxes) and exclusion (orange boxes) criteria for the EndoQUEST analytic sample.
Pre-surgery (at enrollment) demographics of EndoQUEST participants.
| All Participants (N = 100) | |
|---|---|
| Age at surgery (years) | |
| Mean (SD) | 16.8 (2.3) |
| Median (Min-Max) | 16.0 (12–23) |
| Race, N(%) | |
| White | 94 (94.0) |
| Other/Unknown | 6 (6.0) |
| Ethnicity, N(%) | |
| Hispanic | 5 (5.0) |
| Non-Hispanic | 95 (95.0) |
| Hormone use before surgery, N(%) | |
| No | 8 (8.0) |
| Yes | 92 (92.0) |
| Pain medication use before surgery, N(%) | |
| No | 65 (64.0) |
| Yes | 35 (35.0) |
| Body Mass Index (kg/m2), N(%) | |
| Underweight | 0 (0) |
| Normal weight | 66 (66.0) |
| Overweight | 29 (29.0) |
| Obese | 5 (5.0) |
aHormone medications included combined estrogen/progestin contraceptives, progestin-only pills, norethindrone acetate, medroxyprogesterone acetate, GnRH agonists, and progesterone-containing intrauterine devices.
bRegular pain medication use was defined as ≥1 time/week over a period of ≥3 months. Examples of pain medications included acetaminophen, aspirin, ibuprofen, COX-2 inhibitors, narcotic analgesics, and muscle relaxants.
Surgical and endometriosis-related characteristics of EndoQUEST participants.
| All Participants (N = 100) | |
|---|---|
| Type of endometriosis surgery, N(%) | |
| Second or subsequent surgery | 13 (13.0) |
| First/Diagnostic surgery | 87 (87.0) |
| rASRM stage, N(%) | |
| Stage I/II | 98 (98.0) |
| Stage III/IV | 2 (2.0) |
| Endometriosis surgical sub-phenotype, N(%) | |
| Superficial peritoneal lesion(s) only | 99 (99.0) |
| Deep lesion(s) | 1 (1.0) |
| Endometrioma | 0 (0.0) |
| Years between symptom onset and diagnosis | |
| Median (Min-Max) | 3.1 (0–9) |
| Pain symptoms prompted diagnosis, N(%) | |
| No | 1 (1.0) |
| Yes | 96 (99.0) |
aParticipants were asked “What symptoms, if any, prompted you to see a health care provider before your diagnosis with endometriosis?” with the option of pain, infertility, no symptoms, and other. Three participants were missing whether pain symptoms prompted their endometriosis diagnosis
Comparison of pre- and post-surgery characteristics for participants who completed and did not complete the Y1 post-surgery questionnaire.
| Completed Year 1 post-surgery questionnaire | Did not complete Year 1 post-surgery questionnaire | ||
|---|---|---|---|
| N = 100 | N = 24 | p-value | |
|
| |||
| Age (years) | |||
| Mean (SD) | 16.8 (2.3) | 16.4 (2.4) | 0.52 |
| Race, N(%) | |||
| White | 94 (94.0) | 20 (83.3) | 0.10 |
| Other/Unknown | 6 (6.0) | 4 (16.7) | |
| Ethnicity, N(%) | |||
| Hispanic | 95 (95.0) | 22 (95.7) | 0.99 |
| Non-Hispanic | 5 (5.0) | 1 (4.3) | |
| Hormone use, N(%) | |||
| No | 8 (8.0) | 3 (12.5) | 0.44 |
| Yes | 92 (92.0) | 21 (87.5) | |
| Pain medication use, N(%) | |||
| No | 65 (65.0) | 15 (62.5) | 0.82 |
| Yes | 35 (35.0) | 9 (37.5) | |
| rASRM stage, N(%) | |||
| Stage I/II | 98 (98.0) | 24 (100) | 0.99 |
| Stage III/IV | 1 (2.0) | 0 (0) | |
| Endometriosis surgical sub-phenotype, N(%) | |||
| Superficial peritoneal lesion(s) only | 99 (99.0) | 24 (0) | 0.99 |
| Deep infiltrating | 1 (1.0) | 0 (0) | |
| Age at symptom onset (years) | |||
| Mean (SD) | 13.5 (2.2) | 13.1 (2.1) | 0.46 |
| Time between symptom onset and diagnosis (years) | |||
| Mean (SD) | 3.1 (2.1) | 2.8 (2.0) | 0.63 |
| Type of endometriosis surgery, N(%) | |||
| Second or subsequent surgery | 13 (13.0) | 2 (8.3) | 0.73 |
| First / Diagnostic surgery | 87 (87.0) | 22 (91.7) | |
| SF-12 Mental health component | |||
| Mean (SD) | 43.7 (12.2) | 41.7 (11.2) | 0.49 |
| SF-12 Physical health component | |||
| Mean (SD) | 44.7 (10.8) | 44.6 (9.9) | 0.96 |
| Acyclic pelvic pain in last 3 months, N(%) | |||
| No | 35 (35.0) | 6 (27.3) | 0.47 |
| Yes | 65 (65.0) | 16 (72.7) | |
| Severity of acyclic pelvic pain in last 3 months | |||
| Mean (SD) | 7.6 (2.1) | 7.8 (1.9) | 0.70 |
| Frequency of acyclic pelvic pain in last 3 months, N(%) | |||
| <1 day/month | 4 (6.9) | 2 (11.8) | 0.93 |
| Monthly but not weekly | 15 (25.9) | 4 (23.5) | |
| Weekly | 21 (36.2) | 6 (35.3) | |
| Daily | 18 (31.0) | 5 (29.4) | |
| Acyclic pelvic pain interfered with work/school, N(%) | |||
| No | 21 (35.0) | 3 (17.6) | 0.24 |
| Yes | 39 (65.0) | 14 (82.4) | |
| Acyclic pelvic pain interfered with daily activities at home, N(%) | |||
| No | 24 (40.7) | 5 (29.4) | 0.57 |
| Yes | 35 (59.3) | 12 (70.6) | |
| Reported continuous hormone use in last 3 months, N(%) | |||
| No | 73 (73.0) | 15 (62.5) | 0.32 |
| Yes | 27 (27.0) | 9 (37.5) | |
| Severity of period pain in last 12 months, N(%) | |||
| Mean (SD) | 8.5 (1.5) | 7.9 (2.5) | 0.27 |
| Usual frequency of period pain in last 12 months, N(%) | |||
| Occasionally | 0 (0) | 1 (9.1) | 0.11 |
| Often | 4 (6.7) | 1 (9.1) | |
| Usually | 10 (16.7) | 0 (0) | |
| Always | 46 (76.7) | 9 (81.8) | |
| Maximum severity of acyclic pelvic pain and dysmenorrhea | |||
| Mean (SD) | 8.3 (1.8) | 8.1 (2.2) | 0.75 |
|
| |||
| Hormone use, N(%) | |||
| No | 1 (1.0) | 2 (8.3) | 0.10 |
| Yes | 99 (99.0) | 22 (91.7) | |
| Pain medication use, N(%) | |||
| No | 32 (32.0) | 5 (20.8) | 0.33 |
| Yes | 68 (68.0) | 19 (79.2) | |
| SF-12 Mental health component | |||
| Mean (SD) | 46.9 (11.4) | 46.8 (10.7) | 0.97 |
| SF-12 Physical health component | |||
| Mean (SD) | 48.7 (9.6) | 43.2 (12.5) | 0.02 |
| Maximum severity of acyclic pelvic pain and dysmenorrhea | |||
| Mean (SD) | 5.4 (3.3) | 6.4 (3.4) | 0.22 |
aP-values calculated using T-tests and Fisher’s Exact tests
bPre-surgery characteristics reported on the pre-surgery questionnaire or recorded at endometriosis-related surgery
cMissing data for 3 Year 1 non-completers
dMissing data for 3 Year 1 completers and 3 Year 1 non-completers
eMissing data for 1 Year 1 non-completer
fRestricted to participants who reported acyclic pelvic pain in the last 3 months. Note: Missing data for acyclic pelvic pain severity for 2 Year 1 completers and 1 Year 1 non-completer, missing data for acyclic pelvic pain frequency for 7 Year 1 completers, missing data for acyclic pelvic pain interfering with work/school for 5 Year 1 completers, and missing data for acyclic pelvic pain interfering with daily activities for 6 Year 1 completers
gRestricted to 73 Year 1 completers and 15 Year 1 non-completers who did not report continuous hormone use in the last 3 months. Note: Missing data for period pain severity for 2 Year 1 completers and missing data for period pain frequency for 13 Y1 completers and 4 Year 1 non-completers
hCalculated as the maximum severity of either acyclic pelvic pain in the last 3 months or period pain in the last 12 months. Includes 98 Year 1 completers and 21 Year 1 non-completers
iObtained from the post-surgery questionnaire completed between 6 and 26 weeks after surgery
jMissing data for 5 Year 1 completers and 1 Year 1 non-completers
kCalculated as the maximum severity of either acyclic pelvic pain in the last 3 months or period pain in the last 12 months. Includes 99 Year 1 completers and 24 Year 1 non-completers